Company intelligence / Profile preview
Larkspur Biosciences
Watertown, Massachusetts, United Stateslarkspur.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Larkspur Biosciences is developing precision immunotherapies targeting cancer-intrinsic factors that tumors use to escape immune detection. Their lead development program includes a first-in-class PIP4K2C protein degrader, which was presented at AACR 2024. All programs are currently in preclinical stage.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesProtein degradersMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Larkspur Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Larkspur Biosciences.